Based on the evidence that low doses of IL-2 can increase the endogenous pool of Tregs (109), the combination of a single infusion of autologous ex-vivo expanded polyclonal Tregs with IL-2 or with Liraglutide in patients with T1D is currently under clinical testing (NCT02772679 and NCT03011021). This evidence concerns the gene IL2 and type 1 diabetes mellitus.